Quote this publication Share Print


Opinions on drugs - Posted on Nov 10 2009

Reason for request

Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.


Clinical Benefit


The actual benefit of BYETTA is substantial.

Clinical Added Value


BYETTA provides a minor improvement in actual benefit (IAB IV) in the management of type-2 diabetes in patients treated with a combination of metformin and hypoglycaemic sulphonylurea who have not achieved adequate blood glucose control at the highest tolerated doses of these treatments.

Contact Us

Évaluation des médicaments
All our publications